In Response:
We thank Dr. Wiwanitkit for his comments on our study. 1 The microRNA-based assay described in it requires the quantification of only four RNAs (miR-21, miR-205, and miR-375, and RNU6B). As already noted by us in the publication, this can be conveniently done in any laboratory with a quantitative polymerase chain reaction machine, with time and material costs similar to those for immunohistochemistry-based diagnosis of non-small-cell lung cancer histology. However, the suitability of the assay for biospecimens with less than 90% tumor content has not been assessed by us. In our study, microdissection of tumor-containing regions of biopsied material was performed for 76% of biopsies to have ≥90% tumor content in the specimens that were used for RNA extraction for the microRNAbased assay.
The studies on the association of miR-205 with severe inflammation and benign tumor and the lack of a differential expression of this microRNA between normal and tumor tissues, which Dr. Wiwanitkit refers to, concern oral cancer and not cancer of the lung. In case of the latter, a significantly higher expression of miR-205 in lung squamous cell carcinoma tissue compared with normal lung, or lung tissue with adenocarcinoma or benign diseases has been noted by many [2] [3] [4] [5] and in Figure 1 of our article. 
We would like to thank Dr. Tapias and Dr. Lanuti for their comments on our recent article reporting on a multicenter cohort of 68 patients with solitary fibrous tumors of the pleura (SFTP), who were analyzed for the complete course of the disease in a routine practice setting. 1 We acknowledge that our recurrence rate of 30% 
